IDH1 and acute myeloid leukemia: This patient was the first patient in the world treated on the initial Phase I first-in-human clinical trial of olutasidenib at the starting dose level of 150 mg daily (the on-label starting dose is 150 mg BID) for R/R IDH1 mutated AML.